SWOG Network Group Operations Center of the NCTN

NCTN SWOG 网络集团运营中心

基本信息

批准号：
10159079
负责人：
CHARLES D. BLANKE
金额：
$ 793.3万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-17 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10159079
关键词：
Accountability Advocate Affect Applications Grants Behavior Biology Canada Clinical Clinical Research Clinical Trials Communities Development Disease Enrollment Ensure Ethics Fostering Foundations Funding Future Generations Goals Grant Human Immune Knowledge Lead Leadership Malignant Neoplasms Mentors Mexico Mission Modality NCI-Designated Cancer Center National Clinical Trials Network Neoplasms Oncology Pathway interactions Patients Persons Physicians Problem Solving Publishing Regimen Research Research Personnel Saudi Arabia Science Site South America South Korea Southwest Oncology Group Therapeutic Trials Time Training and Education Translational Research Translational trial United States United States Food and Drug Administration Work cancer clinical trial cancer therapy career cost effective design experience improved innovation member neoplastic next generation operation programs standard of care tool translational scientist

项目摘要

The impact statement in SWOG's network operations grant application succinctly summarizes our work and our goals: By continuously improving inclusion, engagement, and scientific innovation, SWOG will enhance cancer clinical trial development and conduct, reducing the burden of human neoplasm. The SWOG National Clinical Trials Network Group has established itself as an innovative, collaborative, a n d cost-effective NCTN constituent. SWOG has 60 years of trial experience, and its work has led to the Food and Drug Administration approval of 14 regimens, changing and informing oncologic practice hundreds of time more. In our 2013 grant application, we promised to make unique contributions to the new NCTN enterprise, and we successfully did so over the last five years. We are strongly committed to furthering our efforts over the next six. SWOG designs and directs high-value, pathway- and immune- driven oncology research, with the goal of achieving practice-changing results that are meaningful to both persons affected by cancer and investigators. The group's current network includes more than 1,000 member sites, with 5,000 physicians who practice across the United States, Canada, South Korea, Mexico, Saudi Arabia, and South America. Twenty-three NCI-designated cancer centers number among our members, as do 22 Specialized Programs in Oncology Research Excellence. From early 2014 through mid-2017, SWOG investigators published more than 188 cancer treatment articles and abstracts, and enrolled 12,819 patients into NCTN therapeutic trials. SWOG actively collaborates in NCTN direct research and administrative functions and has developed training and education tools used throughout the network. SWOG's mission is to significantly improve lives through cancer clinical trials and translational research. The following guiding principles, ratified in 9/2017, are the foundation upon which we build to achieve that end: — We make patients our absolute highest priority — We ensure that the best science drives our research — We embrace and encourage diversity in leadership and membership, to effectively solve problems in cancer — We demand integrity, accountability, and ethical behavior in SWOG — We foster and mentor young investigators, to ensure excellent clinical research for future generations Over the next grant cycle, we will provide an efficient, innovative, and nimble network capable of developing and conducting abroad framework of clinical and translational trials; we will meaningfully contribute to the NCTN; and we will help patients lead longer and meaningful lives. SWOG will remain an innovative force in the design of the next generation of oncologic therapies.

SWOG 网络运营拨款申请中的影响声明简洁地总结了我们的工作我们的目标：通过不断提高包容性、参与度和科学创新， SWOG将加强癌症临床试验的开发和开展，减轻人类的负担肿瘤。 SWOG 国家临床试验网络小组已将自己打造为一个创新、协作、且具有成本效益的 NCTN 成员拥有 60 年的试验经验，其工作导致了美国食品和药物管理局批准 14 种治疗方案，改变并告知肿瘤学实践在 2013 年的拨款申请中，我们曾数百次承诺为该项目做出独特的贡献。新的 NCTN 企业，我们在过去五年中成功做到了这一点，我们坚定地致力于这一点。在接下来的六个阶段进一步努力设计和指导高价值、途径和免疫。推动肿瘤学研究，目标是实现对双方都有意义的改变实践的结果该组织目前的网络包括 1,000 多名癌症患者和研究人员。会员网站，拥有 5,000 名医生，在美国、加拿大、韩国、墨西哥、沙特阿拉伯和南美洲有 23 个 NCI 指定癌症中心。成员，以及从 2014 年初到 22 个肿瘤学研究卓越专业项目。 2017 年中期，SWOG 研究人员发表了超过 188 篇癌症治疗文章和摘要，并且 SWOG 已将 12,819 名患者纳入 NCTN 治疗试验，并积极与 NCTN 直接合作。研究和行政职能，并开发了在整个过程中使用的培训和教育工具网络。 SWOG 的使命是通过癌症临床试验和转化显着改善生活 9/2017 年批准的以下指导原则是我们开展工作的基础。达到这个目的： — 我们将患者视为绝对的首要任务 — 我们确保最好的科学推动我们的研究 — 我们拥抱并鼓励领导层和成员的多样性，以有效解决问题在癌症中 — 我们要求 SWOG 中的诚信、问责制和道德行为 — 我们培养和指导年轻的研究人员，以确保为子孙后代提供出色的临床研究在下一个资助周期中，我们将提供一个高效、创新和灵活的网络，能够我们将制定和开展国外临床和转化试验框架；为 NCTN 做出有意义的贡献；我们将帮助患者过上更长久、更有意义的生活。仍将是下一代肿瘤治疗设计的创新力量。